These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 27176725

  • 1. A randomized double-blind multi-center trial of hydrogen water for Parkinson's disease: protocol and baseline characteristics.
    Yoritaka A, Abe T, Ohtsuka C, Maeda T, Hirayama M, Watanabe H, Saiki H, Oyama G, Fukae J, Shimo Y, Hatano T, Kawajiri S, Okuma Y, Machida Y, Miwa H, Suzuki C, Kazama A, Tomiyama M, Kihara T, Hirasawa M, Shimura H, Hattori N.
    BMC Neurol; 2016 May 12; 16():66. PubMed ID: 27176725
    [Abstract] [Full Text] [Related]

  • 2. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S, Parkinson Study Group.
    J Neurol; 2005 Oct 12; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [Abstract] [Full Text] [Related]

  • 3. Pilot study of H₂ therapy in Parkinson's disease: a randomized double-blind placebo-controlled trial.
    Yoritaka A, Takanashi M, Hirayama M, Nakahara T, Ohta S, Hattori N.
    Mov Disord; 2013 Jun 12; 28(6):836-9. PubMed ID: 23400965
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial.
    LeWitt PA, Hauser RA, Pahwa R, Isaacson SH, Fernandez HH, Lew M, Saint-Hilaire M, Pourcher E, Lopez-Manzanares L, Waters C, Rudzínska M, Sedkov A, Batycky R, Oh C, SPAN-PD Study Investigators.
    Lancet Neurol; 2019 Feb 12; 18(2):145-154. PubMed ID: 30663606
    [Abstract] [Full Text] [Related]

  • 5. Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study.
    Verschuur CV, Suwijn SR, Post B, Dijkgraaf M, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Deuschl G, Lang AE, de Haan RJ, de Bie RM.
    BMC Neurol; 2015 Nov 19; 15():236. PubMed ID: 26584951
    [Abstract] [Full Text] [Related]

  • 6. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
    Pahwa R, Lyons KE, Hauser RA, Fahn S, Jankovic J, Pourcher E, Hsu A, O'Connell M, Kell S, Gupta S, APEX-PD Investigators.
    Parkinsonism Relat Disord; 2014 Feb 19; 20(2):142-8. PubMed ID: 24055014
    [Abstract] [Full Text] [Related]

  • 7. [A multi-centered randomized double-blinded controlled clinical study on efficacy of gulling pa'an capsule in treating Parkinson's disease].
    Zhao GH, Meng QG, Yu XD.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Jul 19; 29(7):590-4. PubMed ID: 19852288
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
    Hattori N, Takeda A, Takeda S, Nishimura A, Kato M, Mochizuki H, Nagai M, Takahashi R.
    Parkinsonism Relat Disord; 2018 Aug 19; 53():21-27. PubMed ID: 29748109
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study.
    Hattori N, Tsuboi Y, Yamamoto A, Sasagawa Y, Nomoto M, ME2125-3 Study Group.
    Parkinsonism Relat Disord; 2020 Jun 19; 75():17-23. PubMed ID: 32446176
    [Abstract] [Full Text] [Related]

  • 10. Levodopa and the progression of Parkinson's disease.
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group.
    N Engl J Med; 2004 Dec 09; 351(24):2498-508. PubMed ID: 15590952
    [Abstract] [Full Text] [Related]

  • 11. Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease.
    Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, van Laar T, Tissingh G, Munts AG, Deuschl G, Lang AE, Dijkgraaf MGW, de Haan RJ, de Bie RMA, LEAP Study Group.
    N Engl J Med; 2019 Jan 24; 380(4):315-324. PubMed ID: 30673543
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of rotigotine transdermal patch for the treatment of apathy and motor symptoms in Parkinson's disease.
    Hauser RA, Slawek J, Barone P, Dohin E, Surmann E, Asgharnejad M, Bauer L.
    BMC Neurol; 2016 Jun 07; 16():90. PubMed ID: 27267880
    [Abstract] [Full Text] [Related]

  • 13. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, PKDS009 Study Group.
    CNS Drugs; 2004 Jun 07; 18(11):733-46. PubMed ID: 15330687
    [Abstract] [Full Text] [Related]

  • 14. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R, Tanner CM, Hauser RA, Sethi K, Isaacson S, Truong D, Struck L, Ruby AE, McClure NL, Went GT, Stempien MJ.
    Mov Disord; 2015 May 07; 30(6):788-95. PubMed ID: 25650051
    [Abstract] [Full Text] [Related]

  • 15. Randomized double-blind placebo-controlled trial of hydrogen inhalation for Parkinson's disease: a pilot study.
    Yoritaka A, Kobayashi Y, Hayashi T, Saiki S, Hattori N.
    Neurol Sci; 2021 Nov 07; 42(11):4767-4770. PubMed ID: 34319514
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease.
    Ostrem JL, Ziman N, Galifianakis NB, Starr PA, Luciano MS, Katz M, Racine CA, Martin AJ, Markun LC, Larson PS.
    J Neurosurg; 2016 Apr 07; 124(4):908-16. PubMed ID: 26495947
    [Abstract] [Full Text] [Related]

  • 17. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
    Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD.
    Drugs; 1998 Apr 07; 55 Suppl 1():23-30. PubMed ID: 9483167
    [Abstract] [Full Text] [Related]

  • 18. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q, Tan Y, Xu P, Tao E, Lu Z, Pan X, Wang B, Liu C, Dong X, Tian Y, Sun X, Cattaneo C, Chen S, Shang H, XINDI Study Investigators Group.
    CNS Drugs; 2022 Nov 07; 36(11):1217-1227. PubMed ID: 36346534
    [Abstract] [Full Text] [Related]

  • 19. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
    Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F, Tolosa E, Eyal E, Weiss YM, Olanow CW.
    Lancet Neurol; 2011 May 07; 10(5):415-23. PubMed ID: 21482191
    [Abstract] [Full Text] [Related]

  • 20. Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind study.
    Mizuno Y, Nomoto M, Hasegawa K, Hattori N, Kondo T, Murata M, Takeuchi M, Takahashi M, Tomida T, Rotigotine Trial Group.
    Parkinsonism Relat Disord; 2014 Dec 07; 20(12):1388-93. PubMed ID: 25455692
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.